Company Profile
Scholar Rock Stock Price, News & Analysis
- Ticker:
- SRRK
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
52.64 USD (+9.96%)
Close
Last updated: August 6, 2026
5.35B USD
Market cap
Why the stock is moving
The latest monitored company update is “Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decis….” The corresponding closing-price reaction is not yet available.
Company overview
Myostatin Biology
Scholar Rock develops therapies that selectively modulate growth factors in their latent forms. Its lead work targets myostatin to improve muscle function while preserving related signaling pathways.
Apitegromab
Apitegromab is a selective inhibitor of latent myostatin under FDA review for children and adults with spinal muscular atrophy. It is designed as an add-on to therapies that address the underlying genetic cause.
Additional Pipeline
Scholar Rock is applying its platform to additional neuromuscular and metabolic indications where modulation of muscle biology may provide clinical benefit.
Future catalysts
FDA action on the apitegromab BLA by September 30, 2026.
Potential U.S. launch of apitegromab immediately following approval.
Recent news
- 01
- 02
- 03
Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference
Source: Scholar Rock
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Scholar Rock (SRRK)?
Scholar Rock (SRRK) most recently closed at 52.64 USD, a +9.96% move versus the previous session.
What is the market cap of Scholar Rock (SRRK)?
Scholar Rock currently has a market capitalization of 5.35B USD on BioPharmSignal.
What does Scholar Rock do?
Myostatin Biology Scholar Rock develops therapies that selectively modulate growth factors in their latent forms. Its lead work targets myostatin to improve muscle function while preserving related signaling pathways. Apitegromab Apitegromab is a selective inhibitor of latent myostatin under FDA review for children and adults with spinal muscular atrophy....
On which exchange is SRRK stock listed?
Scholar Rock (SRRK) is associated with NASDAQ, United States, Biopharma.
What is apitegromab?
FDA action on the apitegromab BLA by September 30, 2026.
Which conditions is Scholar Rock targeting with apitegromab?
Scholar Rock is associated with metabolic disease, genetic disease based on its company overview and current catalyst commentary.
How does Scholar Rock describe recent progress with apitegromab?
FDA action on the apitegromab BLA by September 30, 2026.
What is Myostatin?
Myostatin Biology Scholar Rock develops therapies that selectively modulate growth factors in their latent forms.